Skip to search formSkip to main contentSkip to account menu

ECOG performance status

Known as: ECOG Score, ECOG1-Performance Status, ECOG101 
A performance status scale designed to assess disease progression and its affect on the daily living abilities of the patient.
National Institutes of Health

Related topics

Related topics

3 relations
CDISC Questionnaire ECOG Test Code TerminologyClinical Data Interchange Standards Consortium TerminologyZubrod Performance Status

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
EXTENDED FOLLOW‐UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG‐ACRIN RESEARCH GROUP (E4412)
phoma (Frank, Cancer Discov, 2018). Ibrutinib compromises B-cell survival by inhibiting Bruton’s tyrosine kinase, but also… 
Review
2019
Review
2019
Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy.
2019
2019
Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin‐2 use in solid tumors: A feasibility off‐label experience
2018
2018
Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real‐world practice
As second‐line therapy, regorafenib has been shown to provide a survival benefit for patients with hepatocellular carcinoma (HCC… 
2015
2015
Risk of acute myocardial infarction after androgen‐deprivation therapy for prostate cancer in a Chinese population
To investigate the risk of acute myocardial infarction (AMI) after androgen‐deprivation therapy (ADT) for prostate cancer in a… 
2015
2015
Tolerability and outcomes of curative radiotherapy in patients aged 85 or more years
Objectives: To assess the tolerability and survival outcome of curative radiotherapy in patients over the age of 85 years. 
2013
2013
Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
Review
2013
Review
2013
Radiotherapy for stage III non-small-cell lung carcinoma in the elderly (age ≥ 70 years).
2011
2011
Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology…
Study Type – Therapy (case series) 
Level of Evidence 4 
2008
2008
Phase 2 trial of docetaxel and gefitinib in the first‐line treatment of patients with advanced nonsmall‐cell lung cancer (NSCLC) who are 70 years of age or older
This is a phase 2 study of chemotherapy‐naive patients, 70 years of age or older, with nonsmall‐cell lung cancer (NSCLC) who were… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)